Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iberdomide + obinutuzumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**iberdomide + obinutuzumab** is an investigational combination of a small molecule immunomodulatory drug (iberdomide) and a humanized type II anti-CD20 monoclonal antibody (obinutuzumab) used in clinical studies for patients with relapsed or refractory (R/R) lymphoma, including aggressive B-cell non-Hodgkin lymphoma (NHL), follicular lymphoma, and marginal zone lymphoma. **Iberdomide** acts as a modulator/degrader of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors essential for lymphocyte development, leading to immunomodulation and antitumor activity. **Obinutuzumab** targets the CD20 antigen on B cells and mediates B-cell depletion through enhanced antibody-dependent cellular cytotoxicity (ADCC), direct non-apoptotic cell death via lysosomal destabilization, and, to a lesser extent, complement-dependent cytotoxicity (CDC). The combination is intended to provide synergistic immunomodulation and immune-mediated cytotoxicity to improve efficacy in B-cell malignancies[1][3][2][4][6][8].
- Other names
- iberdomide + obinutuzumab
02
Targets
CD20 (B-lymphocyte antigen CD20)IKZF3 (Zinc finger protein Aiolos)IKZF1 (Ikaros family zinc finger protein 1)CRBN (Cereblon)
Beyond the preview
Go deeper on iberdomide + obinutuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iberdomide + obinutuzumab.